January 10, 2010
Männedorf, Switzerland, January 10, 2012 -
Tecan's Infinite® M1000 multimode microplate reader has
enabled scientists in the Department of Cellular Biology
and Anatomy at Georgia Health Sciences University (GHSU),
USA, to develop a high throughput system for reporter-based
drug screening assays in living zebrafish disease models1.
Dr Jeff Mumm, Assistant Professor at GHSU, explained:
"Quantitative microplate reader systems have revolutionized
the pace of drug discovery, enabling the development of
reporter-based in vitro and in silico assays that allow
high throughput screening (HTS). However, biological
validation has become a bottleneck in the drug discovery
process, due to a lack of HTS-compatible in vivo assay
platforms. Quantifying reporter levels in living zebrafish
provides a versatile means of alleviating this road
block."
"The flexibility of the Infinite M1000 has allowed us to
develop a simple and cost-effective automated screening
method based on fluorescent or luminescent reporter
detection in live zebrafish. Using this method we have been
able to quantify the loss and regeneration of targeted
cells in zebrafish disease models, as well as small
molecule-induced changes in disease-linked molecular
signaling pathways. High signal to noise ratios allow us to
monitor changes in individual fish - which accounts for
wide reporter level variance across populations by
normalizing signals to each individual's ground state -
enabling us to detect long-term changes over several days.
This powerful technique will benefit a wide variety of high
throughput chemical and genetic screens in live zebrafish,
potentially accelerating the validation of new drugs."
To find out more on Tecan's Infinite M1000, visit
1Walker SL, et al. (2012) Automated Reporter Quantification
In Vivo: High-Throughput Screening Method for
Reporter-Based Assays in Zebrafish. PLoS ONE, published 04
Jan 2012.
Tecan Trading AG
Tanja Sager
Seestrasse 103
CH-8708 Männedorf
About Tecan
) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).
distribué par | Ce noodl a été diffusé par Tecan Group AG et initialement mise en ligne sur le site http://www.tecan.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-10 14:37:47 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |